The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some
eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep
Schering’s licensing deals secure. Was it the right move?
2009/03/13
Merck Takes Unusual Merger Tactic in Schering Deal
Genentech and Roche May Be Close to Deal
Roche raised their bid for the biotech last Friday to $93 dollars per share, luring Genentech back to
the negotiating table.
Astellas to Nominate Two Directors to CV Therapeutics Board
Astellas’s hostile bid takes a new turn as the Japanese company tries to oust remaining CVT board
members and replace them with their own.
Budgeting Brands in Troubled Times
Companies are tightening their purse strings just when brand strategies need to target new
audiences
GSK Garners FDA Warning Letter for Extraterrestrial Ad Campaign
GlaxoSmithKline received a warning letter for use of misleading imagery in its television ad for
Avodart. The Feds felt that comparing prostate size to planets might not be a good idea.
2009/02/20
Stream Power
Convert future revenue into present value with alternative approaches to access capital.
"AIM" High and Win
If traditional advertising and PR tactics are falling short, a community-based marketing strategy
could be the thing to put your brand back in the game.
Chantix Bounced From McCann to McGarry Bowen
Pfizer switched agencies for its popular smoking cessation drug Chantix. While the company is tight
lipped about the campaign’s new direction, it looks like this may be the end of the tortoise and hare. Does this
signal an end to the use of critters in pharma ads?
Sanofi-Aventis and AZ Launch YouTube Sites
Two pharma companies dabble in online video in two different but effective ways. Sanofi-aventis
attempts to reach patients through educational videos, while AZ calls for consumers to upload their own
testimonials.